Shanghai Shyndec Pharmaceutical Co., Ltd. (SHANGHAI SHYNDEC PHARMACEUTICAL) aksje

Shanghai Shyndec Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical products in China. The company provides nifedipine controlled release tablets, penicillin industrial potassium salt, touboke yuekui granules/capsules, sodium cefuroxime for injection, D-7ACA, fermented products, milnacipran hydrochloride tablets, compound licorice tablets, and cefoperazone dispersible tablets; and cefuroxime axetil tablets, cefuroxime sodium for injection, cefaclor extended-release capsules, cefixime granules, and cefdinir dispersible tablets. It also offers nifedipine controlled-release tablets, amlodipine besylate tablets, enalapril maleate tablet, pravastatin sodium tablets, olmesartan medoxomil hydrochlorothiazide tablets, olmesartan amlodipine tablets; milnaprom hydrochloride tablets, lofen codeine tablets, gastrodin injection, naloxone hydrochloride injection, piracetam injection; and apmis film, tacrolimus capsules, mannan peptide for injection, imatinib mesylate. In addition, the company provides methylprednisolone sodium succinate for injection, octreotide acetate injection, betamethasone sodium phosphate for injection, dexamethasone sodium phosphate injection; diclofenac sodium sustained release tablets; 6-aminopenicillinic acid, azithromycin, amoxicillin, potassium clavulanate microcrystalline cellulose, ceftriaxone sodium crude salt, 7-aminocephalosporanic acid, chorionic gonadotropin, urinary gonadotropin; and naphazoline hydrochloride nasal drops, Ambroxol Hydrochloride Oral Solution. Shanghai Shyndec Pharmaceutical Co., Ltd. was founded in 1996 and is based in Shanghai, China.